Trima Accel
Device Apheresis
PDI 05020583810020
General payments
$255,930
Research payments
$6,955
Through program year 2024, $255,930 in general payments and $6,955 in research payments were reported against Trima Accel (Apheresis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $65,164 | 20 |
| 2023 | General | $59,422 | 25 |
| 2023 | Research | $6,955 | 1 |
| 2022 | General | $55,897 | 29 |
| 2021 | General | $75,447 | 18 |
Breakdown
The top 5 of 11 recipients; each share is of general payments naming this product in 2024.
Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 8 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
92 general · 1 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.